Consortium of Multiple Sclerosis Centers (CMSC) - May 31-June 3, 2023 / Aurora, CO
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Clinical Outcomes with Evobrutinib in Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase 2 Open-Label Extension
Montalban | Oral #DMT04
Immune Response Following COVID-19 Vaccination (mRNA or Non-mRNA) in Evobrutinib-Treated Patients with RMS: An Update
Bar-Or | Poster #DMT16
Efficacy in Clinical and MRI Outcomes with Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis (MAGNIFY-MS)
De Stefano | Poster #DMT44
Pregnancy and Infant Outcomes from an Ongoing Worldwide Surveillance Program of Cladribine Tablets: 5-Year Pharmacovigilance Results from MAPLE-MS
Hellwig | Poster #DMT24
A Long-Term Study Evaluating Safety and Efficacy of Evobrutinib in Relapsing Multiple Sclerosis (LONGEVO)
Montalban | Poster #DMT48W
The Next Generation Learning Health System for Multiple Sclerosis (Next-Gen MS): Using Patient Reported Data to Improve MS Care and Outcomes
Oliver | Poster #QOL14W
Cladribine Tablets After Treatment with Natalizumab (CLADRINA) Trial – Clinical Analysis
Sguigna | Poster # LB16
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
Help us direct you to the right information by selecting one of the following options: